Clinical Trial Update: Investigation of the Safety and Tolerability of BSCT (Anti-nf-P2X7) 10% Ointment [Phase 1]

View source ↗

Summary

Phase 1 study assessing safety and tolerability of a 10% BSCT ointment targeting nf-P2X7 in basal cell carcinoma; study completed with results posted in 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Basal Cell Carcinoma

Drugs mentioned

• BSCT (Anti-nf-P2X7 10% ointment)

Snippet

Sponsor: Biosceptre | Conditions: Carcinoma, Basal Cell (BCC) | Phase 1 | Status: COMPLETED | Results posted: 2016-03-15